Ecuador Medical Device Sanctions: Article 72 and the Consequences of Suspension or Cancellation

1. Key takeaways

The new regulation contains no penalty articles of its own. Through Article 72 it refers sanctions back to the Organic Health Law: violations of the regulation are sanctioned under that law and other laws in force, without prejudice to any civil, administrative and criminal liability that may arise.

A second layer sits in general provision two (SEGUNDA), which provides that the suspension or cancellation of a registration certificate implies a prohibition on manufacturing, importing and exporting the device, immediate withdrawal from the market and confiscation. Those consequences attach to the administrative act itself and do not depend on a separate sanction decision.

The same general provision requires ARCSA to publish the registration status of devices on its website, including certificates that are valid, suspended and cancelled. Enforcement in Ecuador is therefore visible to the market at the moment it happens, and the commercial damage usually runs ahead of the fine.

2. Legal basis

Substance of the second sentence of general provision two: the suspension or cancellation of a medical device registration certificate implies a prohibition on manufacturing, importing and exporting the device, immediate withdrawal from the market and confiscation, carried out in accordance with the Organic Health Law.

3. Expert insights

Insight one: liability under Article 72 is triple. The text provides that violations are sanctioned under the Organic Health Law and other laws in force, without prejudice to the civil, administrative and criminal sanctions to which they may give rise (sin perjuicio de las sanciones civiles, administrativas y penales a las que hubiera lugar). Beyond the administrative penalty, damages claims and criminal exposure remain fully available.

Insight two: the four collateral consequences of general provision two hurt more than a fine. Once a certificate is suspended or cancelled, four consequences follow automatically: no manufacturing, no import, no export, immediate withdrawal from the market, plus confiscation. The inclusion of export deserves attention, because stock held in Ecuador cannot be shipped out to another market to limit the loss.

Insight three: publication turns a sanction into a market event. The first sentence of general provision two requires ARCSA to publish valid, suspended and cancelled device registrations on its website. Competitors, procurement departments and healthcare institutions can check the status instantly, so the reputational effect usually exceeds the value of the penalty itself.

Insight four: the two refusal grounds in Article 30 operate upstream. Registration is refused for devices containing components prohibited nationally or internationally, on a list published by ARCSA, and for devices subject to health alerts (alertas sanitarias). Article 39, item (b) adds a procedural consequence: a product that has previously been the subject of an alert or a suspension must, at renewal, file an additional sworn declaration with legal certification.

Insight five: inspection and sampling are the main discovery channel. The inspections under Articles 64 to 66, including Type 2 laboratory analysis, cover manufacturing, storage, distribution, commercialisation, transport, dispensing and sales premises and may include sampling. Article 67 requires the holder to keep the full technical file available at all times, so a missing file is itself a violation and can be the trigger for everything that follows.

Insight six: Article 39 ties a past alert to future renewal difficulty. For a product that has been subject to an alert or a suspension, renewal does not follow the automatic procedure in Article 38; the holder must file a system certificate, a sworn declaration and other supplementary material. An enforcement record therefore keeps charging compliance cost for years after the event.

4. Practical recommendations

1. Make the existence of any health alert a mandatory pre-filing check, and re-verify alert status every month.
2. Keep the full technical file available under Article 67, with a retrieval time short enough for an unannounced inspection.
3. Monitor the registration status published on the ARCSA website, and trigger the contingency plan immediately if a suspension or cancellation appears.
4. Include a sanctions indemnity in the contract with the holder, covering withdrawal, confiscation and reputational loss.
5. Feed alert history into renewal planning: for a previously alerted product, prepare the Article 39 supplementary material well in advance.

5. Verification checklist

• □ The health alert status of the product has been checked before filing
• □ The full technical file is kept locally under Article 67
• □ The registration status page on the ARCSA website is subscribed to or checked periodically
• □ The holder contract contains a sanctions indemnity clause
• □ Article 39 supplementary material has been prepared for products previously subject to an alert
• □ The exposure to triple liability (civil, administrative and criminal) has been assessed

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation